Kn Manohar, Agarwal Ramshyam, Patange Aparana, Rao Pariksha, Ganu Gayatri, Khan Kaynat, Sawant Sanjana
Diabetes and Endocrinology, Manipal Hospitals, Bangalore, IND.
General Medicine, Lokmanya Medical Research Center, Pune, IND.
Cureus. 2025 Apr 20;17(4):e82613. doi: 10.7759/cureus.82613. eCollection 2025 Apr.
Obesity is closely associated with metabolic syndrome, a cluster of conditions including abdominal obesity, high triglycerides, low high-density lipoprotein (HDL) cholesterol, elevated blood pressure, and impaired glucose metabolism. Emerging research suggests that gut dysbiosis, an imbalance in gut microbiota, plays a key role in metabolic syndrome, influencing insulin resistance, inflammation, and lipid metabolism. The gut microbiome has gained attention for its impact on energy balance, fat storage, and metabolic regulation. This randomized, double-blind, placebo-controlled, multicentric clinical study evaluated the efficacy and safety of probiotic-fiber blend formulation in obese adults.
Obese adults (body mass index (BMI) 30-<40 kg/m², aged 30-45; male: 46.15%, female: 53.85%) were randomly assigned to receive either the probiotic-fiber blend formulation or a placebo for 90 days, along with lifestyle counseling. Primary outcomes included body weight, BMI, waist/hip circumference, and body fat percentage. Secondary outcomes assessed biochemical parameters, digestive health, quality of life, perceived stress, and metabolic syndrome severity Z (MetS-Z) score. One hundred four participants completed the study.
The probiotic-fiber blend formulation (n = 53) demonstrated statistically significant (p < 0.001) improvements compared to placebo (n = 51), including reductions in body weight (12.01%), BMI (12.14%), waist circumference (9.64%), and hip circumference (9.63%) compared to placebo. Additionally, statistically significant reductions were observed in the MetS-Z score (54.02%), triglycerides (25.75%), and perceived stress (37.62%), along with a notable increase in HDL levels (16.55%). Significant improvements in digestive health and quality of life were also recorded, reinforcing the probiotic-fiber blend efficacy.
The findings provide robust evidence that the probiotic-fiber blend effectively improves anthropometric and biochemical markers in obesity. These results underscore the therapeutic potential of gut microbiome modulation in metabolic health. Further research should explore long-term effects, mechanistic pathways, and broader clinical applications.
肥胖与代谢综合征密切相关，代谢综合征是一组病症，包括腹部肥胖、高甘油三酯、低高密度脂蛋白（HDL）胆固醇、血压升高和葡萄糖代谢受损。新兴研究表明，肠道菌群失调，即肠道微生物群失衡，在代谢综合征中起关键作用，影响胰岛素抵抗、炎症和脂质代谢。肠道微生物组因其对能量平衡、脂肪储存和代谢调节的影响而受到关注。这项随机、双盲、安慰剂对照、多中心临床研究评估了益生菌-纤维混合制剂在肥胖成年人中的疗效和安全性。
肥胖成年人（体重指数（BMI）30-<40kg/m²，年龄30-45岁；男性：46.15%，女性：53.85%）被随机分配接受益生菌-纤维混合制剂或安慰剂，为期90天，并接受生活方式咨询。主要结局包括体重、BMI、腰臀围和体脂百分比。次要结局评估生化参数、消化健康、生活质量、感知压力和代谢综合征严重程度Z（MetS-Z）评分。104名参与者完成了研究。
与安慰剂组（n = 51）相比，益生菌-纤维混合制剂组（n = 53）显示出具有统计学意义（p < 0.001）的改善，包括体重（降低12.01%）、BMI（降低12.14%）、腰围（降低9.64%）和臀围（降低9.63%）。此外，MetS-Z评分（降低54.02%）、甘油三酯（降低25.75%）和感知压力（降低37.62%）也有统计学意义的降低，同时HDL水平显著升高（升高16.55%）。消化健康和生活质量也有显著改善，进一步证明了益生菌-纤维混合制剂的疗效。
研究结果提供了有力证据，表明益生菌-纤维混合制剂可有效改善肥胖患者的人体测量和生化指标。这些结果强调了调节肠道微生物组对代谢健康的治疗潜力。进一步的研究应探索其长期影响、作用机制途径和更广泛的临床应用。
